Clinical features of secondary acute myeloid leukemia in children
https://doi.org/10.17650/1818-8346-2020-15-4-12-17
Abstract
Background. Secondary malignancies in pediatric cancer survivors is an actual problem in modern oncopediatry. Alkylating agents and topoisomerase II inhibitors used for primary tumors treatment, induce secondary acute myeloid leukemia (sAML), which treatment results are unsatisfactory.
Objective. By predicating on literature and own data to evaluate clinical and biologic features and therapeutic potential of pediatric sAML.
Materials and methods. Six patients (age 7–16 years) with sAML were enrolled the study from June 1998 to December 2016. Follow up until September 2020. Primary tumors, which therapy could induce sAML were acute lymphoblastic leukemia, Burkitt lymphoma, germ cell tumor, osteosarcoma, nephroblastoma.
Results and conclusion. From 6 patients, included in the study, 2 are alive (+58 and +67 months after allogenic stem cell transplantation), that match global data. Fludarabine-containing regimens and allogeneic hematopoietic stem cell transplant could be a method of choice for this unfavorable group of patients.
About the Authors
F. A. Makhacheva
Pediatric Oncology and Hematology Research Institute, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
T. T. Valiev
Pediatric Oncology and Hematology Research Institute, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
References
1. Inskip P.D., Curtis R.E. New malignancies following childhood cancer in the United States, 1973–2002. Int J Cancer 2007;121(10):2233–40. DOI: 10.1002/ijc.22827.
2. Hijiya N., Ness K.K., Ribeiro R.C. Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues. Cancer 2009;115(1):23–35. DOI: 10.1002/cncr.23988.
3. Bhatia S. Therapy-related myelodysplasia and acute myeloid leukemia. Semin Oncol 2013;40(6):666–75. DOI: 10.1053/j.seminoncol.2013.09.013.
4. Advani P.G., Schonfeld S.J. Risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia after childhood cancer: a population-based study. Leukemia 2019;33(12):2947–78. DOI: 10.1038/s41375-019-0520-y.
5. Lee S.S. Therapy-related acute myeloid leukemia following treatment for Burkitt’s lymphoma. Chonnam Med J 2017;53(3):229–30. DOI: 10.4068/cmj.2017.53.3.229.
6. McNerney M.E., Godley L.A., Le Beau M.M. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer 2017;17(9):513–27. DOI: 10.1038/nrc.2017.60.
7. Agarwal R., Liebe S., Turski M.L. et al. Targeted therapy for genetic cancer syndromes: Von Hippel–Lindau disease, Cowden syndrome, and Proteus syndrome. Discov Med 2015;19(103):109–16.
8. Nemirovchenko V.S., Shervashidze M.A., Valiev T.T., Kondratchik K.L. Treatment results of pediatric acute myeloid leukemia with epigenetic drugs addition. Onkogematologiya = Oncohematology 2020;15(2):19–28. (In Russ.). DOI: 10.17650/1818-83462020-15-2-19-28.
Review
For citations:
Makhacheva F.A., Valiev T.T. Clinical features of secondary acute myeloid leukemia in children. Oncohematology. 2020;15(4):12-17. (In Russ.) https://doi.org/10.17650/1818-8346-2020-15-4-12-17
Views:
9964
Email this article 